Stakeholder Perspectives on the Development and Implementation of a Polypharmacy Management Program in Germany: Results of a Qualitative Study

T.S. Dinh*, M.S. Brueckle, A.I. Gonzalez-Gonzalez, J. Witte, M. Van den Akker, F.M. Gerlach, C. Muth, EVITA Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Structured management programs have been developed for single diseases but rarely for patients with multiple medications. We conducted a qualitative study to investigate the views of stakeholders on the development and implementation of a polypharmacy management program in Germany. Overall, we interviewed ten experts in the fields of health policy and clinical practice. Using content analysis, we identified inclusion criteria for the selection of suitable patients, the individual elements that should make up such a program, healthcare providers and stakeholders that should be involved, and factors that may support or hinder the program's implementation. All stakeholders were well aware of polypharmacy-related risks and challenges, as well as the urgent need for change. Intervention strategies should address all levels of care and include all concerned patients, caregivers, healthcare providers and stakeholders, and involved parties should agree on a joint approach.
Original languageEnglish
Article number1115
Number of pages16
JournalJournal of Personalized Medicine
Volume12
Issue number7
DOIs
Publication statusPublished - 1 Jul 2022

Keywords

  • medication management
  • multimorbidity
  • polypharmacy
  • qualitative research
  • stakeholder analysis
  • structured care program

Cite this